Solid Biosciences Inc. SLDB

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
42/100
Developing

Ranked against 712 peers in Biotechnology

About Solid Biosciences Inc.

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that … Full SLDB analysis →

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 0.84), with margins expanding over time.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.62), providing operational cushion.

Key risks

  • ROIC Below WACC or Peers ROIC at 31.5th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.22), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
40
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where SLDB ranks in Biotechnology

Solid Biosciences Inc. ranks #340 of 713 scored companies in Biotechnology by moat score — the top 48%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
336 Neuphoria Therapeutics Inc. NEUP 43/100 Developing
337 Rocket Pharmaceuticals, Inc. RCKT 43/100 Developing
338 Vaxcyte, Inc. PCVX 43/100 Developing
339 Chemomab Therapeutics Ltd. CMMB 42/100 Developing
340 Solid Biosciences Inc. SLDB 42/100 Developing
341 60 Degrees Pharmaceuticals, Inc SXTP 42/100 Developing
342 BioLineRx Ltd. BLRX 42/100 Developing
343 Prelude Therapeutics Incorporat PRLD 42/100 Developing
344 Fate Therapeutics, Inc. FATE 42/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How SLDB scores on the Corporate Default defenses

Pricing Power

Score 40 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 39 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 36 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 31 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 36 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 75 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding SLDB's moat

What is Solid Biosciences Inc.'s moat score?

Solid Biosciences Inc. (SLDB) scores 42 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #340 of 713 scored companies in Biotechnology, the top 48%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (75/100) and its weakest is Capital Efficiency (31/100).

How does Solid Biosciences Inc. compare with other Biotechnology companies?

Solid Biosciences Inc. ranks #340 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Chemomab Therapeutics Ltd. (CMMB) at 42 just above it and 60 Degrees Pharmaceuticals, Inc (SXTP) at 42 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Solid Biosciences Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Solid Biosciences Inc.?

The Corporate Default template measures 6 defenses, and SLDB scores: Pricing Power (40), Cost Advantage (39), Customer Stickiness (36), Capital Efficiency (31), Resilience (36), Scale & Market Position (75). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000